Company news
Inovio Pharmaceuticals, Inc. news in 2019
Inovio Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results
November 11, 2019
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
November 4, 2019
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
September 16, 2019
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
August 18, 2019
Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
August 7, 2019
Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019
July 29, 2019
Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates
July 15, 2019
Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
July 7, 2019
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
June 25, 2019
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
June 9, 2019
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
May 15, 2019
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
May 14, 2019
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
May 5, 2019
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
April 30, 2019
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development
April 7, 2019
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
April 2, 2019
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
April 1, 2019
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
March 31, 2019